

Medivir Q1 2025 - Calm Quarter Awaiting Phase IIb

Redeye comments on Medivir's Q1 report, during which the main events were the completion of the phase IIa study of fostrox in combination with Lenvima and the licensing deal signed by Medivir's partner Infex in India.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Medivir Q1 2025 - Calm Quarter Awaiting Phase IIb